Xynos Konstantinos 4
4 · Replimune Group, Inc. · Filed Dec 5, 2022
Insider Transaction Report
Form 4
Xynos Konstantinos
Chief Medical Officer
Transactions
- Award
Employee Stock Option (right to buy)
2022-12-01+26,250→ 26,250 totalExercise: $19.98Exp: 2032-12-01→ Common Stock (26,250 underlying) - Award
Common Stock
2022-12-01+17,500→ 70,798 total
Footnotes (2)
- [F1]Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on November 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until November 15, 2026, subject to the Reporting Person's continuous service to the Issuer.
- [F2]25% of the shares underlying this stock option vest on December 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.